Genetics of heart rate in heart failure patients (GenHRate) by Evans, Kaleigh L et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Research Articles Research Administration 
5-21-2019 
Genetics of heart rate in heart failure patients (GenHRate). 
Kaleigh L. Evans 
Heidi S. Wirtz 
Jia Li 
Henry Ford Health System, jli4@hfhs.org 
Ruicong She 
Henry Ford Health System, rshe1@hfhs.org 
Juan Maya 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/research_articles 
Recommended Citation 
Evans KL, Wirtz HS, Li J, She R, Maya J, Gui H, Hamer A, Depre C, and Lanfear DE. Genetics of heart rate in 
heart failure patients (GenHRate). Hum Genomics 2019; 13(1):22. 
This Article is brought to you for free and open access by the Research Administration at Henry Ford Health 
System Scholarly Commons. It has been accepted for inclusion in Research Articles by an authorized administrator 
of Henry Ford Health System Scholarly Commons. 
Authors 
Kaleigh L. Evans, Heidi S. Wirtz, Jia Li, Ruicong She, Juan Maya, Hongsheng Gui, Andrew Hamer, 
Christophe Depre, and David E. Lanfear 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
research_articles/35 
PRIMARY RESEARCH Open Access
Genetics of heart rate in heart failure
patients (GenHRate)
Kaleigh L. Evans1, Heidi S. Wirtz2, Jia Li3, Ruicong She3, Juan Maya2, Hongsheng Gui4, Andrew Hamer2,
Christophe Depre2 and David E. Lanfear1,4,5*
Abstract
Background: Elevated resting heart rate (HR) is a risk factor and therapeutic target in patients with heart failure
(HF) and reduced ejection fraction (HFrEF). Previous studies indicate a genetic contribution to HR in population
samples but there is little data in patients with HFrEF.
Methods: Patients who met Framingham criteria for HF and had an ejection fraction < 50% were prospectively
enrolled in a genetic HF registry (2007–2015, n = 1060). All participants donated blood for DNA and underwent
genome-wide genotyping with additional variants called via imputation. We performed testing of previously
identified variant “hits” (43 loci) as well as a genome-wide association (GWAS) of HR, adjusted for race, using
Efficient Mixed-Model Association Expedited (EMMAX).
Results: The cohort was 35% female, 51% African American, and averaged 68 years of age. There was a 2 beats per
minute (bpm) difference in HR by race, AA being slightly higher. Among 43 candidate variants, 4 single nucleotide
polymorphisms (SNPs) in one gene (GJA1) were significantly associated with HR. In genome-wide testing, one statistically
significant association peak was identified on chromosome 22q13, with strongest SNP rs535263906 (p = 3.3 × 10−8). The
peak is located within the gene Cadherin EGF LAG Seven-Pass G-Type Receptor 1 (CELSR1), encoding a cadherin super-
family cell surface protein identified in GWAS of other phenotypes (e.g., stroke). The highest associated SNP was specific
to the African American population.
Conclusions: These data confirm GJA1 association with HR in the setting of HFrEF and identify novel candidate genes for
HR in HFrEF patients, particularly CELSR1. These associations should be tested in additional cohorts.
Keywords: Genetics, Heart rate, African Americans, Single nucleotide polymorphisms
Introduction
Heart failure (HF) remains a considerable public health
problem, with an estimated 5.7 million people living
with HF in the USA, resulting in > 1 million HF hospi-
talizations and > $30 billion in health care costs annually
[1]. Chronic HF is associated with repeated hospitali-
zations, substantially reduced quality of life, and a yearly
mortality rate in the USA of 7.5% [2]. Observational and
interventional studies in adults demonstrate that ele-
vated heart rate (HR) is a modifiable risk factor in
patients with HF [3–6]. Beta-blockers represent one of
the most important therapeutic options for reducing
morbidity and mortality in HF, which may partly be con-
tributed to by their capacity to reduce HR. More recently,
the Systolic Heart treatment with the If inhibitor ivabradine
Trial (SHIFT) demonstrated that specifically targeting HR
reduction in HF patients with reduced ejection fraction
(HFrEF) lowers the risk of hospitalization for worsening
HF, establishing HR as not only a marker of risk but a
treatment target [6]. Therefore, understanding the
genetic and biologic drivers of HR particularly in the
setting of HFrEF may aid in understanding HF patho-
physiology, improve prognostication, or inform treat-
ment decision-making.
Previous studies have examined genetic factors influen-
cing HR in various settings. It has recently become clear
that HR is a heritable trait [7, 8], suggesting important
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genetic influences. In the context of beta-blocker (BB)
therapy, GRK5 was suspected of influencing this but in
one study showed no association of GRK5 genotype with
heart rate [9]. Several GWAS of HR in non-HF popu-
lations have been performed [10–14], which have reported
a number of significant variants; however, the impact of
these loci in HF patients remains uncharacterized; and to
our knowledge, the genetic contribution to HR in patients
with established HFrEF has not been previously investi-
gated. The overall goal of this study was to test the validity
of previous candidate gene associations and to identify
novel genetic determinants of HR in a diverse cohort of
HFrEF patients via GWAS.
Methods
Study population
The study population (n = 1060) was from a genetic
registry of HF patients collected at the Henry Ford
Health System (September 13, 2007 to April 1, 2015). Entry
criteria included patients ≥ 18 years of age meeting the
Framingham criteria for HF, with a previously measured
left ventricular ejection fraction (LVEF) < 50%, who were
enrolled in our covered entity (Health Alliance Plan) for at
least 1 year prior to the date of registry enrollment. Left
ventricular EF < 50% was used as eligibility criteria because
at the time of registry initiation, this was considered stand-
ard for systolic HF. Since EF cutoffs for HFrEF have sub-
sequently changed and ivabradine is indicated in EF < 35%,
we include additional restricted analyses in this group. The
study was approved by local ethics committees and partici-
pants provided written informed consent.
Genotyping and imputation
We performed genotyping on all registry participants
using the Axiom Biobank array (Affymetrix®). This array
contains 600K single nucleotide polymorphisms (SNPs)
including: (1) 300K GWAS markers with minor allele
frequencies of > 1%, (2) > 250K markers low frequency
(< 1%) coding variants from the exome sequencing
project, and (3) an additional 50K variants to improve
African ancestry coverage (YRI Booster). This array pro-
vides excellent coverage of genomic variation, capturing
90% in European ancestry and ~ 80% in African ancestry
patients. It also allows for ancestral quantification and
admixture mapping. The genotyping and standard qua-
lity checks were carried out in a standard accepted
fashion. In brief, SNPs with a minor allele frequency less
than 0.01 or not in Hardy–Weinberg equilibrium (HWE,
P < 1 × 10−7) in each major ethnicity group were
removed. Multi-allelic sites and ambiguous SNPs were
also deleted. Additionally, study participant samples with
questioned validity due to either sex inconsistency
(between reported and genetically inferred) or duplicate
genotyping were removed.
The imputation was conducted on the Michigan Im-
putation Server. The computation engine is Minimac3
(https://genome.sph.umich.edu/wiki/Minimac3), and the
reference panel used was 1000 Genome Phase 3 v5 [15].
Following imputation, we assessed accuracy at each
SNP as the squared Pearson correlation (R2) between
the masked genotypes and the imputed allele dosages
(also known as posterior mean genotypes). We retained
variants passing commonly used imputation quality
thresholds (R2 > 0.3, MAF > 0.01, HWE P value > 1 × 10−7)
for use in the subsequent analyses.
Clinical data
Patient characteristics including demographic, medical,
and lifestyle data were collected at registry enrollment
via a standardized questionnaire and physical exam and
supplemented by using administrative data maintained
by the system. Primary data collection via the question-
naire and study staff assessment included age, sex, HR,
blood pressure, New York Heart Association class,
self-identified race, and co-morbidities. We utilized elec-
tronic administrative databases maintained by HFHS
(including data from Health Alliance Plan our covered
entity), such as patient encounters, medical claims,
laboratory data, and pharmacy claims membership files
to supplement primary data collection from the patient.
This included medical diagnoses established via ICD-9
diagnosis related groupings (DRG). ICD-9 classification
does not contain discriminators for permanent vs. par-
oxysmal atrial arrhythmias. In patients with a history of
atrial fibrillation diagnostic/billing codes, diagnosis
additional data was collected and reviewed (clinical
ECG’s), and additional sensitivity analyses were performed
as described below. HR was a single measurement
obtained as a resting pulse rate measured by hand or with
an automatic blood pressure cuff by a qualified study
personnel during physical exam at registry enrollment.
The assessment of possible non-sinus rhythm (see
adjusted analyses below) was done by querying all avail-
able ECG data in the system for patients with previous
diagnoses of atrial arrhythmia, reviewing ECG tracings
temporally closest to, and surrounding enrollment date
(i.e., both before and after the enrollment date). We
classified patients as likely or unlikely to be in non-sinus
rhythm, and this was used as an excluding factor in a
secondary analysis. To quantify beta-blocker exposure
for adjusted analyses, we chose to use the average
beta-blocker exposure over 6 months prior to enroll-
ment. This was accomplished using pharmacy claims
data to generate a beta-blocker exposure metric as pre-
viously described [16]. This metric summarizes exposure
(both dose and adherence) of all BB medications as a
proportion of target exposure for HFrEF (per consen-
sus guidelines). Regarding individual agent use, among
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patients on BB carvedilol (39%) and metoprolol succinate
(38%) were most frequently used, but there were smaller
groups of patients using metoprolol tartrate (18%) or
another beta-blocker (4%).
Statistical analysis
We first sought to assess previously published genetic loci
for HR found by other GWAS studies (in non-heart
failure patients) and test for significance in our HFrEF co-
hort. We reviewed literature for GWAS studies published
that identified significant loci for HR. We found five pub-
lications [10–14] that identified a total of 43 loci (listed in
Additional file 1: Table S1). We tested the association of
these genotypes using linear regression adjusted for
self-identified race and kinship. For this analysis, we used
the Bonferroni correction for 43 multiple comparisons,
which yields a critical P value threshold of 1.16 × 10−3.
The primary objective of our study was to identify
individual SNPs and genes associated with resting HR,
adjusted for race (since this was associated with HR).
We used Efficient Mixed-Model Association eXpedited
(EMMAX) analyses for genome-wide association ana-
lysis [17]. This approach uses a kinship matrix to take
into account population structure and relatedness. Asso-
ciations with P < 5 × 10−8 were considered genome-wide
significant [18]. We performed several adjusted and
sensitivity analyses to mitigate the contribution of poten-
tial confounders and assess the robustness of our findings.
First, we repeated our primary analysis excluding patients
that may have had non-sinus rhythm (e.g., atrial fibril-
lation or flutter) upon enrollment. Next, we performed
similar analyses adjusted for beta-blocker exposure
(quantified as described above).
We secondarily also took a gene-based analytic approach,
combining the data from all SNPs within each gene region
using the SNP-set kernel-machine association test (SKAT)
[19]. This method uses a logistic kernel-machine model,
aggregating individual score test statistics of SNPs, and
provides a global P value for the set of variants tested that
takes into account the joint effect of the SNPs in a given
SNP set. Gene regions were defined based upon the
GENCODE annotation [20]. Multiple comparisons were
accounted for using the false discovery rate method of
Benjamini-Hochberg [21].
Results
The study cohort baseline characteristics are shown in
Table 1. Overall, the cohort was 35% female and 51% AA
and had an average age of 68 years. We tested HR diffe-
rences by race which revealed a clinically small but statis-
tically significant difference in HR by race, with African
Americans having on average around 2 bpm higher rates
(70 ± 13 vs. 72 ± 13 bpm; P = 0.0021). As expected, several
characteristics varied across the two racial groups, inclu-
ding HF etiology, co-morbidities, and demographics.
Identified from previous reports of GWAS of HR,
we tested 43 previously implicated loci in our cohort
of HFrEF patients. In total, the association with HR
for four of these SNPs were replicated in our study,
with P values ranging from 2.55 × 10−4 to 7.75 × 10−5
(Bonferroni corrected critical P value threshold 1.16 ×
10−3). All four of these SNPS were within a single re-
gion of chromosome 6, within the gene GJA1 which
encodes connexin 43. The SNP ID, P value, and ori-
ginal publication citation for these significant loci are
listed in Table 2.








Female 374 (35%) 220 (41%) 154 (30%) 0.001
Age 68 (± 12) 65 (± 12) 71 (± 11) 0.001
Ejection fraction (%) 34.9 (± 11) 33.6 (± 11.4) 36.2 (± 10.4) 0.001
Ischemic etiology 608 (57%) 267 (49%) 341 (66%) 0.001
Hx COPD 234 (22%) 114 (21%) 120 (23%) 0.375
Hx CKD 239 (± 23%) 149 (± 27.4) 90 (± 17.4) 0.001
Hx A-Fib 295 (28%) 104 (19%) 191 (37%) 0.001
Hx stroke/TIA 129 (12%) 69 (12.7%) 60 (11.6%) 0.375
Hx diabetes 441 (42%) 250 (46%) 191 (37%) 0.003
Sys BP (mmHg) 129 ± 23 131 ± 24 126 ± 22 0.002
HR (beats per min.) 71.1 ± 13 72.2 ± 13 69.9 ± 13 0.007
NTproBNP (ng/L) 348 (± 374) 336 (± 386) 362 (± 360) 0.001
Creatinine (mg/dL) 1.29 1.36 (± 1.08) 1.17 (± 0.57) 0.003
BB exposurea 0.26 (± 0.29) 0.26 (± 0.3) 0.26 (± 0.29) 0.832
aThis is the proportion of target BB exposure over 6 months in patients taking BB
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Genome-wide analyses of genotype influence on heart rate
The analysis was adjusted for self-identified race (African
American or white) and the analytic method accounted
for population stratification and relatedness of individuals
(i.e., kinship). These primary results (model 1) are
depicted in the Manhattan plot in Fig. 1 (Q-Q plot
depicted in Fig. 2). The top 20 SNPs associated with heart
rate are listed in Table 3, showing the allele frequencies
and effect sizes, and whether the SNP was present in only
one racial group or not. One locus, rs535263906 on
chromosome 22q13, met the genome-wide statistical
significance (p = 3.3 × 10−8). A zoomed in view (1Mb) of
this association peak is shown in Fig. 3. This association
peak lies within the gene Cadherin EGF LAG Seven-Pass
G-Type Receptor 1 (CELSR1), though there are a number
of other genes nearby.
There were two additional association peaks that were
close to statistical significance in the primary analysis.
One was on chromosome 5 centered on rs541284506
(P = 9.5 × 10−8), and another was on chromosome 6 with
the strongest SNP being rs149447933 (P = 7.5 × 10−8).
These peaks were somewhat broad, did not have clear
supporting base of SNPs, and did not locate within a
known coding gene; the closest being roughly 200 kb
from s149447933 on Chr6 (a non-coding RNA gene,
LINC01108). Close up (1 Mb) images of these two
peaks are shown in Additional file 2: Figure S1 and
Additional file 3: Figure S2. There were an additional
138 SNPs with levels of association considered
suggestive (P < 10−5), a full listing of which are included in
Additional file 1: Table S2. Finally, we stratified model 1
by race (Additional file 1: Tables S6 and S7).
Sensitivity and other additional analyses
We performed several additional genome wide analyses
to mitigate any contributions from possible confounding
factors and assess the robustness of the above findings.
First, we performed a subgroup analysis excluding
patients classified as possible non- sinus rhythm. Because
ECG was not obtained as part of study enrollment and
thus could not guarantee sinus rhythm in all subjects, we
performed additional investigations collecting and exa-
mining all clinically available ECG in patients with any
prior diagnosis of atrial arrhythmia. These patients
were classified as possible non-sinus or likely sinus
based on ECG evidence of heart rhythm near the
time of enrollment. We then repeated our primary
statistical analysis excluding patients deemed as possible
non-sinus rhythm. This analysis (model 2) has results
shown in Fig. 4 and the top 20 loci listed in Table 4.
Another key secondary analysis was similar to the primary
analysis (i.e., all subjects) but adjusted for beta-blocker
exposure (model 3). These results are depicted in Fig. 5
and top loci listed in Table 5. Overall, the results of
models 2 and 3 appear similar to the results of the primary
analysis (model 1). We still see the same three loci of
potential interest though there is variation in terms of
priority and whether they meet genome-wide statistical
Table 2 Replication of other GWAS studies in HFrEF patients
Gene P value SNP Source
GJA1 7.75 × 10−5 rs9398652 Eijgelsheim et al. [10], Deo et al. [11]
GJA1 9.10 × 10−5 rs12110693 Deo et al. [11]
GJA1 9.40 × 10−5 rs1015451 Kilpelainen [12]
GJA1 2.55 × 10−4 rs9320841 Deo et al. [11]
Fig. 1 Manhattan plot of GWAS results from model 1: SNP + race + kinship (n = 1043; AA = 520, white = 523). Blue reference line: 1 × 10−5; red
reference line: 5 × 10−8
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Fig. 2 Q-Q plot of primary GWAS analysis
Table 3 Top 20 GWAS results from model 1: SNP + race + kinship (n = 1043; AA = 520, white = 523)
SNP A1 A2 MAF_AA MAF_W MAF_All Coef P value Group
rs535263906 A G 0.02381 NA 0.02381 14.768 3.30E−08 AA only
rs149447933 G C 0.01524 NA NA 17.793 7.51E−08 AA only
rs541284506 A G 0.01714 NA NA 17.652 9.52E−08 AA only
rs11006544 C T 0.01714 NA NA 16.175 2.27E−07 AA only
rs112434206 G A 0.02286 NA NA 14.598 2.77E−07 AA only
rs11110004 C T 0.01143 NA NA 19.543 2.97E−07 AA only
rs114821210 A C 0.01714 NA NA 15.695 5.30E−07 AA only
rs74056623 A G 0.05238 NA NA 9.270 6.46E−07 AA only
rs148133894 C T 0.00952 NA NA 20.479 8.64E−07 AA only
rs189919070 T C 0.00762 NA NA 22.822 9.33E−07 AA only
rs74864598 A C 0.09524 0.01912 0.05725 5.793 1.01E−06 Complete
rs16917667 A G 0.09524 0.01912 0.05725 5.793 1.01E−06 Complete
rs74056624 A G 0.04952 NA NA 9.318 1.06E−06 AA only
rs149322277 T C 0.02286 NA NA 13.281 1.14E−06 AA only
rs188344082 A G 0.04952 NA NA 9.287 1.16E−06 AA only
rs150381023 C T 0.02 NA NA 14.152 1.21E−06 AA only
rs150109621 T C 0.02 NA NA 14.152 1.21E−06 AA only
rs8105292 C T 0.3371 0.1128 0.2252 3.433 1.28E−06 Complete
rs139130723 G A 0.01714 NA NA 15.126 1.33E−06 AA only
rs142803096 C G 0.01714 NA 0.01714 15.126 1.33E−06 AA only
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Fig. 3 1 MB view of statistically significant peak on chromosome 22 with gene tracks overlaid
Fig. 4 Manhattan plot of GWAS results from model 2: SNP + race + kinship; excluding possible non-sinus patients (n = 901; AA = 484, white = 417).
Blue reference line 1 × 10−5; red reference line 5 × 10−8
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significance. Specifically, the most strongly associated SNP
in model 1 was still so for model 2 (rs541284506) but was
third in model 3, achieving P = 9.97 × 10−8), while
rs149447933 achieved statistical significance in this model
(P = 6.29 × 10−9).
We also performed an additional subgroup analysis
restricted to patients with EF ≤ 35% (n = 589). The ana-
lysis of this much smaller group yielded no variants that
met whole genome significance. There was one locus
with two SNPs in proximity to each other, rs76008716
Table 4 Top 20 GWAS results from model 2: SNP + race + kinship; excluding possible non-sinus patients (n = 901; AA = 484,
white = 417)
SNP A1 A2 MAF_AA MAF_W MAF_All Coef P value Group
rs535263906 A G 0.02381 NA NA 15.372 2.94E−08 AA only
rs149447933 G C 0.01524 NA NA 18.040 1.12E−07 AA only
rs541284506 A G 0.01714 NA NA 18.282 1.97E−07 AA only
rs11110004 C T 0.01143 NA NA 19.375 3.39E−07 AA only
rs79031501 C T NA 0.02294 NA 14.281 4.33E−07 EA only
rs965460 G A NA 0.02294 NA 14.281 4.33E−07 EA only
rs114726259 T C NA 0.02199 NA 14.281 4.33E−07 EA only
rs148467525 A G 0.01429 NA NA 18.407 4.99E−07 AA only
rs8105292 C T 0.3371 0.1128 0.2252 3.687 7.52E−07 Complete
rs78829380 T C 0.06571 NA NA 8.326 7.89E−07 AA only
rs111681691 T C 0.02381 0.0392 0.03149 8.908 8.67E−07 Complete
rs148133894 C T 0.00952 NA NA 20.344 9.22E−07 AA only
rs189566544 C A 0.0219 NA NA 14.624 9.43E−07 AA only
rs11006544 C T 0.01714 NA NA 15.681 9.98E−07 AA only
rs150381023 C T 0.02 NA NA 14.870 1.08E−06 AA only
rs150109621 T C 0.02 NA NA 14.870 1.08E−06 AA only
rs112434206 G A 0.02286 NA NA 14.067 1.20E−06 AA only
rs117130066 A G NA 0.02677 NA 12.323 1.23E−06 EA only
rs74866062 C A NA 0.01625 NA 16.806 1.24E−06 EA only
rs117289820 C G NA 0.01625 0.01625 16.806 1.24E−06 EA only
Fig. 5 Manhattan plot of GWAS results from model 3: SNP + race + kinship + BB exposure (n = 990; AA = 494, white = 496). Blue reference
line 1 × 10−5; red reference line 5 × 10−8
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and rs57957360, which were near statistical significance
(P = 5.4 × 10−8) and had not appeared in the top loci of
other analyses. We performed a sensitivity analysis treat-
ing HR as an ordinal variable (rather than continuous
variable), thereby mitigating the influence of very low
or very high values and not overestimating precision
of measure. These results were overall similar to the
above with two of the top three SNPs being the same
(Additional file 1: Table S5).
Gene-wise analysis of heart rate
As an alternative approach to try to identify genes
impacting heart rate, we performed another genome-
wide analysis testing gene regions rather than individual
SNPs. A total of 42,774 genes/functional genomic
regions were defined based upon the ENCODE project
annotation. The critical P value for global error rate was
1.17 × 10−6, and overall results are depicted in Additional
file 4: Figure S3 (Q-Q plot depicted in Additional file 5:
Figure S4). No genes met genome-wide significance. The
top 40 genes, which had P < 0.001, are shown in
Additional file 1: Table S3. There were four genes with
P values < 1 × 10−4. All four of these gene regions are cur-
rently of unknown function (Additional file 1: Table S4).
One gene on chromosome 12 (C12orf74) was predicted to
be a protein-encoding gene, though its structure and func-
tion remain unknown. The other three gene-regions of
interest were in non-coding RNA genes, also of unknown
function.
Discussion
Although similar types of studies have been performed
previously in population samples [10–13], our study is
the first that we know of to attempt to identify genomic
regions that influence HR in stable patients with HFrEF.
Analysis of this diverse patient cohort revealed a modest
but statistically significant difference in HR between
self-identifying white and AAs (with AA showing a
slightly higher HR) as well as three genomic loci at or
near genome-wide significance in at least one analysis
for association to HR, of particular interest is a novel
locus on Chr. 22q13 in the gene CELSR1.
Putting this study in context of pre-existing work, we
were able to replicate one of the previously published
genetic loci, in the gene GJA1, which had been reported
to be associated with resting HR in multiple studies.
This not only reconfirms the validity of this association
but also suggests that GJA1 genetic variation may have
impact on HR in patients with HFrEF. High resting heart
rate is a well-recognized modifiable risk factor for
cardiovascular morbidity and mortality in heart failure
patients [3–6]. GJA1 encodes connexin 43, a connexin
family protein and a major component of the cardiac
gap junction which is a central in the electrical coupling
Table 5 Top 20 GWAS results from model 3: SNP + race + kinship + BB exposure (n = 990; AA = 494, white = 496)
SNP A1 A2 MAF_AA MAF_EA MAF_All Coef P value Group
rs149447933 G C 0.01524 NA NA 19.714 6.29E−09 AA only
rs541284506 A G 0.01714 NA NA 17.634 8.59E−08 AA only
rs535263906 A G 0.02381 NA NA 14.516 9.12E−08 AA only
rs187251765 A C 0.01333 NA NA 19.092 1.88E−07 AA only
rs139130723 G A 0.01714 NA NA 16.629 2.04E−07 AA only
rs142803096 C G 0.01714 NA NA 16.629 2.04E−07 AA only
rs11006544 C T 0.01714 NA NA 16.148 2.15E−07 AA only
rs11110004 C T 0.01143 NA NA 19.544 2.60E−07 AA only
rs112434206 G A 0.02286 NA NA 14.507 3.12E−07 AA only
rs6498482 T C 0.3752 0.588 0.4814 − 2.987 3.16E−07 Complete
rs143554223 G A 0.01333 NA NA 19.333 3.56E−07 AA only
rs148467525 A G 0.01333 NA NA 19.333 3.56E−07 AA only
rs188482801 A C 0.03238 NA NA 12.604 3.81E−07 AA only
rs74056623 A G 0.05238 NA NA 9.378 5.55E−07 AA only
rs114821210 A C 0.01714 NA NA 15.541 6.32E−07 AA only
rs7188980 C T 0.4143 0.6195 0.5167 2.859 6.63E−07 Complete
rs148133894 C T 0.00952 NA NA 20.392 8.60E−07 AA only
rs74056624 A G 0.04952 NA NA 9.350 9.24E−07 AA only
rs188344082 A G 0.04952 NA NA 9.389 1.03E−06 AA only
rs189919070 T C 0.00762 NA NA 22.630 1.06E−06 AA only
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of cardiac myocytes [22]. The fact that we did not repli-
cate the other GW significant hits from previous studies
could be due in part to the relatively smaller size of our
cohort, but importantly, there are design differences that
may also contribute to differential findings. Most im-
portant is that this cohort was all the HFrEF patients,
and the genetic factors influencing HR may be different
in the setting of this disease. This is in fact the primary
reason we performed this analysis, to attempt to identify
HR mechanism relevant to HF that may thus impact
therapy or patient outcomes. Another important diffe-
rence is the fact that our cohort is racially diverse while
most previous studies were in only patients of European
ancestry. This diverse cohort allows us to potentially
detect important associations that may be amplified or
selective to AA patients and is another potential reason
for differential finding in ours vs. previous studies. The
strongest associated loci are in fact specific to African
American patients in this cohort.
The SNP-wise GWA analysis identified two SNPs that
met whole genome significance for association with HR
in one or more models (see Tables 3–5) and another that
was very close in each analysis. The strongest association
appeared to be for the association peak on Chr 22. The
peak SNP in this analysis (rs535263906) was only
present and tested in African American patient samples,
and while imputed (rather than directly genotyped), it
was of high imputation confidence (R2 = 0.816) and had
a supporting peak of SNPs beneath it. This association
peak is near a large number of genes but lies almost
completely within CELSR1, which encodes a receptor of
the cadherin super-family and appears to have gene
expression (mRNA) in a wide range of tissues including in
cardiac and smooth muscle cells (The Genotype-Tissue
Expression [GTEx] project). The association peak encom-
passes most of the 5′ half of CELSR1, so attempting to
infer possible functional impact of the yet unidentified
causative variant (presumably linked to rs535263906 but
accounting for the phenotype association) would be
speculative and remains the work of future investigation.
Interestingly, CELSR1 has been reported in other GWAS
studies as being associated with a variety of traits; these
include stroke [23] and a suggestive association with feno-
fibrate response in diabetics [24]. Further investigation
into this gene and the other candidates is needed to assess
their possible cardiac functional impact. While whole-gen-
ome significance was met, these findings should be viewed
as preliminary until they can be tested for validation in an-
other data set. Unfortunately, another similar data set,
particularly including African Americans with HFrEF is
not readily available to the investigative team.
Although no statistical significance was reached in the
gene-wise analysis, these results can be viewed as a
prioritization list for possible association to HR among
HF patients with HFrEF. Similarly, the many additional
individual SNPs that were in the range of possible inter-
est for association with HR (i.e., having P values < 10−6.)
may be of value for future investigation. A high propor-
tion of these loci seemed specific to AA. This could be
due to a higher number of SNPs in AA, statistical
chance, or perhaps because HR is under a stronger
genetic influence in this group of patients. The analysis
of very low EF (< 35%) yielded two additional SNPs of
interests, rs76008716 and rs57957360, which were very
near statistical significance (P = 5.4 × 10−8). These loci
are located in an intergenic region on chromosome 5
and are of unclear biological significance at this point.
The results of this much smaller subcohort should be
interpreted with caution until validated externally.
This study has several limitations. First, it is derived from
a single center cohort of modest size for a GWAS. Mitigat-
ing this is that we are modeling a continuous variable as
endpoint which provides more statistical power compared
to dichotomous or event-driven analyses. In terms of
phenotype, ECG was not performed on the day of enroll-
ment in our study, and pulse rate was used as our HR
measure. For most patients, pulse rate should be a reliable
measure of HR but this may have differences compared to
ECG-derived measures. Moreover, the lack of an ECG
makes it impossible for us to state with certainty that sub-
jects were in sinus rhythm at the time of assessment, but
we have worked hard to mitigate this risk, including add-
itional analyses excluding patients with any history of atrial
arrhythmia. Another potential concern is that we used EF
< 50% as enrollment criteria to categorize patients as
HFrEF. While this is no longer the standard, it was so at
the time of the study initiation and we performed additional
analyses to assess any potential impact. Finally, while we ad-
justed for beta-blocker exposure, we did not have an actual
level the day of enrollment. Despite this, the medication ex-
posure metric used has been previously shown to correlate
to clinical outcomes and inversely correlate with HR [25]
and thus is likely to be a good estimate of true exposure.
Conclusions
In summary, HR in the setting of HFrEF appears to be
impacted by genetic factors. One previous candidate gene
was confirmed in the setting of HFrEF (GJA1), and GWAS
of HR identified several novel genomic loci associated with
HR, particularly a statistically significant peak in the gene
CELSR1. These novel candidate genes for HR in the setting
of HFrEF require additional investigation and validation.
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